The North American Neuroendocrine Tumor Society (NANETS) is pleased to announce that Renata Jaskula-Sztul, Ph.D., assistant professor of surgical oncology at the University of Alabama at Birmingham School of Medicine, has been selected to receive the NANETS Basic/Translational Science Investigator (BTSI) Award. The award was announced at NANETS’ annual symposium, held Oct. 4-6 in Seattle, Washington.
Dr. Renata Jaskula-Sztul
Jaskula-Sztul will receive the grant for her proposal, “Novel Antibody-Drug Conjugate (ADC) for pancreatic Neuroendocrine Tumor (PanNET) Targeted Therapy.” She has published more than 40 papers, and as a co-investigator, she has received funding for five research grants on targeted drug delivery to neuroendocrine tumors.
“Dr. Jaskula-Sztul’s current project on testing antibody-drug conjugates as a potential drug for NET will generate new and exciting information that will form the foundation for future grants,” said NANETS Chair James Howe, M.D.
The $100,000 BTSI Award is funded by the Neuroendocrine Tumor Research Foundation (NETRF), a charitable organization whose mission is to fund research to discover cures and more effective treatments for carcinoid, pancreatic and related neuroendocrine cancers.
The award will be disbursed over the course of two years and will be shared between Jaskula-Sztul and the UAB Department of Biomedical Engineering’s Xiaoguang (Margaret) Liu, Ph.D.
The North American Neuroendocrine Tumor Society is a society of medical professionals with extensive experience in neuroendocrine tumor (NET) disease. The only one its kind in North America and designed by medical professionals on the front lines of the disease, NANETS is a not-for-profit organization founded in 2007 with the mission of improving neuroendocrine tumor (NET) disease management through increased research and educational opportunities.
The Neuroendocrine Tumor Research Foundation is a charitable organization whose mission is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers. Since its inception, the Foundation has awarded more than $14 million in large-scale, multi-year research grants to leading scientists at renowned research institutions, and has funded research at 7 of the top 10 U.S. cancer centers.